Business · 05/06/2023Updated: 10/17/2026 · 1 min read
FDA Announces Revised Draft Guidance for Interstitial Cystitis/Bladder Pain Syndrome Treatment
Summary
The FDA has released a revised draft guidance for industry, outlining recommendations for developing drugs to treat interstitial cystitis/bladder pain syndrome, replacing a previous draft guidance issued in 2019.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →